more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Zacks News

Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

by Zacks Equity Research Published on March 22,2017

Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

Infinity Pharma Focuses on Cancer Drug: Competition Looms

by Zacks Equity Research Published on March 21,2017

We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

Biotech Bull Making a Comeback

by Kevin Cook Published on March 21,2017

A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor

Why Biotech Stock Gilead (GILD) Could Be a Value Trap

by Arpita Dutt Published on March 20,2017

Gilead's (GILD) valuation looks compelling but is the company really poised for

Amgen's Repatha Meets Primary Endpoint in Phase III Study

by Zacks Equity Research Published on March 14,2017

Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).

Alexion's sBLA for Soliris Receives FDA Acknowledgement

by Zacks Equity Research Published on March 10,2017

Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA, on Mar 9, has accepted the supplemental Biologics License Application (sBLA) to expand the indication for Soliris

Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus

by Zacks Equity Research Published on March 10,2017

Epizyme, Inc. (EPZM) reported a loss of 60 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of 64 cents.

Top Research Reports for March 9, 2017

by Mark Vickery Published on March 09,2017

Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Celgene (CELG), and Shell (RDS.A).

Valeant (VRX) Issues Notes, Restructures Debt; Shares Down

by Zacks Equity Research Published on March 08,2017

Valeant Pharmaceuticals International, Inc. (VRX) commenced an offer to purchase cash up to $600 million of aggregate principal amount due 2018.

Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug

by Zacks Equity Research Published on March 08,2017

Seattle Genetics, Inc. (SGEN) announced that the FDA has lifted the clinical hold on two phase I trials of its candidate, vadastuximab talirine (SGN-CD33A; 33A).

Ionis Pharma Lipid Disorder Candidate Positive in Phase III

by Zacks Equity Research Published on March 08,2017

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.

Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara

by Zacks Equity Research Published on March 08,2017

Eli Lilly and Company (LLY) announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson???s Stelara (ustekinumab) in patients with moderate-to-severe plaque.

Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal

by Arpita Dutt Published on March 08,2017

Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.

GlaxoSmithKline's Nucala Positive in Label Expansion Study

by Zacks Equity Research Published on March 07,2017

GlaxoSmithKline plc. (GSK) announced that a phase IIIb study evaluating its respiratory drug Nucala (mepolizumab) met all its primary and secondary endpoints.

Is This the Right Time to Invest in Biotech Stocks?

by Arpita Dutt Published on March 07,2017

The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?

J&J Presents Positive Phase III Data on Psoriasis Candidate

by Zacks Equity Research Published on March 06,2017

Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.

Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4

by Zacks Equity Research Published on March 03,2017

Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.